DURECT Corporation (DRRX)

Quick facts

Phase 3 pipeline

• SABER-Bupivacaine · Pain management
  SABER-Bupivacaine is a sustained-release formulation of bupivacaine, a local anesthetic that blocks nerve impulses.

Phase 2 pipeline

• Bupivacaine HCl Treatment 1c · Pain management
  Bupivacaine HCl is a local anesthetic that works by blocking sodium channels in nerve fibers to prevent the initiation and transmission of nerve impulses.
• Bupivacaine HCl Treatment 2c · Anesthesiology
  Bupivacaine HCl is a local anesthetic that blocks nerve impulses, preventing pain.
• DUR-928 Topical Solution
• EN3270 · Pain
  EN3270 is a small molecule that targets the sigma-1 receptor.
• SABER-Bupivacaine Treatment 1a
• SABER-Bupivacaine Treatment 2a

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• DURECT Corporation portfolio CI brief
• DURECT Corporation pipeline updates RSS